A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers.

Trial Profile

A Multi-Institutional Phase II Study of the Akt Inhibitor MK-2206 in Refractory Biliary Cancers.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2016

At a glance

  • Drugs MK 2206 (Primary)
  • Indications Biliary cancer; Gallbladder cancer; Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 15 Jan 2014 Planned End Date changed from 1 Jan 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
    • 14 Feb 2013 Planned end date changed from 1 Jan 2012 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top